|
注册号: Registration number: |
ChiCTR2600123438 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-27 02:36:22 |
|
注册时间: Date of Registration: |
2026-04-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
沉浸式动静态平衡评估及训练系统治疗脑卒中的初步疗效观察 |
|
Public title: |
Preliminary Observation on the Curative Effect of the Immersive Dynamic and Static Balance Assessment and Training System in the Treatment of Stroke |
|
注册题目简写: |
沉浸式动静态平衡训练治疗脑卒中的疗效 |
|
English Acronym: |
Effects of VR-Based Motor-Cognitive Integrated Training on Stroke Rehabilitation |
|
研究课题的正式科学名称: |
沉浸式动静态平衡评估及训练系统治疗脑卒中的初步疗效观察 |
|
Scientific title: |
Preliminary Observation on the Curative Effect of the Immersive Dynamic and Static Balance Assessment and Training System in the Treatment of Stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵卿 |
研究负责人: |
赵卿 |
|
Applicant: |
Qing Zhao |
Study leader: |
Qing Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 138 1785 7620 |
研究负责人电话:
Study leader's |
+86 21 3773 0011 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhaoqing201304@163.com |
研究负责人电子邮件: Study leader's E-mail: |
qingzhao2010@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市松江区光星路2209号 |
研究负责人通讯地址: |
上海市光星路2209号 |
|
Applicant address: |
No. 2209, Guangxing Road, Songjiang District, Shanghai |
Study leader's address: |
2209 Guangxing Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市养志康复医院(上海市阳光康复中心) |
||
|
Applicant's institution: |
Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center) |
||
|
研究负责人所在单位: |
上海市养志康复医院 |
||
|
Affiliation of the Leader: |
Shanghai Yangzhi rehabilitation hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
养志伦审字〔2025〕015号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市养志康复医院(上海市阳光康复中心)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Yangzhi Rehabilitation Hospital Shanghai Sunshine Rehabilitation Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-24 00:00:00 | ||
|
伦理委员会联系人: |
王涛 |
||
|
Contact Name of the ethic committee: |
Wang Tao |
||
|
伦理委员会联系地址: |
上海市光星路2209号 |
||
|
Contact Address of the ethic committee: |
2209 Guangxing Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3773 0011 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
13644870352@163.com |
|
研究实施负责(组长)单位: |
上海市养志康复医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Yangzhi rehabilitation hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市光星路2209号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2209 Guangxing Road, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
主动健康和老龄化科技应对 |
||||||||||||||||||||||
|
Source(s) of funding: |
Core R&D project sub-topic -R&D of Personalized active Rehabilitation intervetion equipment for EI |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)评价动静态平衡评估及训练系统的安全性及临床应用价值 (2)协助设备后续研发及改良 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To evaluate the safety and clinical application value of the dynamic and static balance assessment and training system.(2) To assist in the subsequent research, development and improvement of the device. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 生命体征不稳定; 2. 严重心、肺、肾、肝等器官疾病; 3. 严重听力、视力异常; 4. 严重焦虑症、抑郁症等精神心理问题; 5. 严重骨关节或肌肉病变者,无法配合完成训练。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Unstable vital signs; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-13 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-30 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究为单盲、对照、单中心临床研究,采用随机化分组,随机化比例:试验组与对照组 1:1。由统计软件SPSS 25设定种子数生成01/02/...62的随机序号以及对应的分组类别,将结果密封于信封内,信封表面只标明序号,信封由专人保管。当受试者完成筛选并符合纳入标准后,按照入组先后顺序拆阅对应编号的信封并记录分组情况,研究者、结果统计分析人员均对分组情况不知情。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This is a single-blind, controlled, single-center clinical study with randomized grouping at a 1:1 ratio between the experimental group and the control group. Random serial numbers from 01, 02, ... to 62 and the corresponding group assignments were generated using the statistical software SPSS 25 with a fixed seed value. The results were sealed in envelopes, with only the serial number marked on the surface. The envelopes were kept by a designated person. After subjects completed screening and met the inclusion criteria, the envelope corresponding to the serial number was opened in the order of enrollment, and the group assignment was recorded. Both investigators and outcome statisticians were blinded to group allocation. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签,对评估者隐藏分组 |
|
Blinding: |
Open-label study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据录入:采集后按规范录入系统,电子采集可设置 “双人录入”(两人分别录入同一数据,系统自动比对差异),纸质采集需专人统一录入并复核。 数据核查: 逻辑核查:系统自动校验数据合理性(如年龄 > 120 岁、用药剂量超出安全范围则触发警报)。 人工核查:监查员定期抽查原始数据与录入数据的一致性,重点核查缺失值、异常值、逻辑矛盾。 疑问管理:对核查发现的问题,通过系统向采集人发送疑问单,采集人补充说明或修正后,监查员确认闭环。 数据清理:修正错误数据、补充缺失数据、标注无法修正的异常值(说明原因),直至数据无疑问。 数据锁定:数据清理完成后,由申办者、研究者、统计师共同确认,锁定数据库,禁止后续修改,锁定后需生成锁定报告。 数据存储与归档: 存储:电子数据加密存储于安全服务器,定期备份(本地 + 异地双备份),设置访问权限;纸质数据扫描电子化后,原件装订归档。 归档:按监管要求留存数据(通常试验结束后至少留存 5 年),归档文件包含原始记录、录入数据、核查报告、锁定报告、修改痕迹等。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data EntryAfter collection, data shall be entered into the system in accordance with specifications. For electronic collection, a "dual-person entry" mode may be adopted — two personnel enter the same data independently, and the system automatically compares and identifies discrepancies. For paper-based collection, designated personnel shall conduct unified entry followed by review.Data VerificationLogical Verification: The system automatically validates data rationality (e.g., triggering an alert if age > 120 years or medication dosage exceeds the safe range).Manual Verification: Monitors conduct regular random checks on the consistency between original data and entered data, focusing on missing values, outliers, and logical contradictions.Query ManagementFor issues identified during verification, queries shall be sent to data collectors via the system. After collectors provide supplementary explanations or make corrections, monitors confirm the closure of each query.Data CleaningCorrect erroneous data, supplement missing data, and label uncorrectable outliers (with reasons specified) until no unresolved issues remain.Data LockingUpon completion of data cleaning, the database shall be jointly confirmed and locked by the sponsor, researchers, and statisticians, prohibiting subsequent modifications. A data locking report must be generated after locking.Data Storage and ArchivingStorage: Electronic data shall be encrypted and stored on secure servers with regular backups (dual backup: local + off-site) and access permission controls. Paper-based data shall be scanned into electronic format, and the original documents shall be bound and filed.Archiving: Data shall be retained in accordance with regulatory requirements (usually for at least 5 years after the end of the trial). Archived documents include original records, entered data, verification reports, locking reports, and modification traces. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |